Juno Therapeutics Inc. (NASDAQ: JUNO) shares continued to surge on Monday after Celgene Corp. (NASDAQ: CELG) had entered into an agreement to acquire Juno for a total of $9 billion or $87 per share. Juno shares rose 27 percent during Monday&rsq..

Shares of the innovative clinical-stage biotechnology company bluebird bio Inc. (NASDAQ: BLUE) have jumped more than 13% Tuesday, after the company together with their partner Celgene Corporation (NASDAQ: CELG) reported updated results from the ongo..